Cell Therapy Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jul 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Immuno-oncology mesodermal progenitor (ioMP) cell (US 10,316,291) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Progenitor cells of mesodermal lineage (US 10,472,609) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Progenitor cells of mesodermal lineage (US 11,873,513) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Method of producing a peripheral blood mononuclear cell composition suitable for repairing or engineering a tissue (US 11,957,384) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,829,739 | Progenitor cells of mesodermal lineage In force · From the USPTO record | In force | From the USPTO record | |
| US 10,472,609 | Progenitor cells of mesodermal lineage In force · From the USPTO record | In force | From the USPTO record | |
| US 11,957,384 | Method of producing a peripheral blood mononuclear cell composition suitable for repairing or engineering a tissue In force · From the USPTO record | In force | From the USPTO record | |
| US 10,117,898 | Platelet lysate gel In force · From the USPTO record | In force | From the USPTO record | |
| US 11,185,348 | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,873,513 | Progenitor cells of mesodermal lineage In force · From the USPTO record | In force | From the USPTO record | |
| US 11,304,981 | Platelet lysate gel In force · From the USPTO record | In force | From the USPTO record | |
| US 10,271,876 | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells In force · From the USPTO record | In force | From the USPTO record | |
| US 12,029,763 | Immuno-modulatory progenitor (IMP) cell In force · From the USPTO record | In force | From the USPTO record | |
| US 10,316,291 | Immuno-oncology mesodermal progenitor (ioMP) cell In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 no status recorded